提醒

提醒专业图表

Tango Therapeutics Inc. (TNGX)

NasdaqGM: TNGX · 实时价格 · USD

25.60

-0.05 (-0.19%)

收盘价： Aug 14, 2026, 3:59 PM

25.60

+0.00%

盘后: 7:34 PM

-0.19% (1D)

买价	21.55
市值	4.32B
营收（TTM）	53.81M
净利润（TTM）	-123.72M
贝塔值	1.15
每股收益（TTM）	-0.84
市盈率（TTM）	n/a
预期市盈率	-15.65
市净率（TTM）	9.43
市销率（TTM）	80.21
Earnings Date	Nov 4, 2026

卖价	36.82
成交量	1,438,869
20日均量	3,837,948
开盘价	25.17
前收盘价	25.65
日内区间	24.75 - 25.69
52周区间	6.25 - 34.39
分析师	Strong Buy
目标价	40 (56.25%)
分红	n/a
除息日	n/a

关于 TNGX

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. ...

[阅读更多]

行业 Biotechnology

板块 Healthcare

上市日期 Sep 3, 2020

员工人数 137

交易所 NasdaqGM

股票代码 TNGX

官网 https://www.tangotx.com

公司完整简介

财务表现

2025年，Tango Therapeutics的营收为62.38M，较上一年的42.07M增长48.29%。净利润为-101.59M，下降-22.03%。

财务报表

分析师预测

根据12位分析师的评级，TNGX的平均评级为“Strong Buy”。12个月目标价为40，较最新价格上涨空间56.25%。

股票预测

财报意外

Tango Therapeutics 已于 Aug 11, 2026 发布季度财报：

营收为 $0 低于预期 $0, ， -100.00% 同比下滑.

每股收益为 -0.37 低于预期 -0.05, ， -5.71% 同比下滑.

下次财报发布时间

Tango Therapeutics Inc. 计划于以下时间发布财报 Nov 4, 2026, 开盘前。
分析师预计营收为 ... 升级

新闻

3天前 · Zacks

TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses

Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.

3周前 · Zacks

How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%

The average of price targets set by Wall Street analysts indicates a potential upside of 49.5% in Tango Therapeutics (TNGX). While the effectiveness of this highly sought-after metric is questionable,...

1月前 · Insider Monkey

Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues

Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 affordable biotech stocks to buy right now. On June 29, Canaccord Genuity increased its target price on Tango Therapeutics Inc. (NASDAQ:TNGX) fro...

1月前 · TipRanks

2 Monster Growth Stocks Analysts Think Can Reach New Highs

There’s no shortage of investing strategies, but growth investing remains one of the most popular approaches. Stocks that climb 50%, 100%, or more over a relatively short period rarely do so by chance...

1月前 · Zacks

Tango Therapeutics Rides a New Precision Oncology Trend in 2026

TNGX is advancing precision oncology with MTAP-targeted therapies and 2026 data readouts that could test its clinical and commercial potential.

第 1 页，共 2 页

Tango Therapeutics Inc. (TNGX)